Latest News and Press Releases
Want to stay updated on the latest news?
-
Conference Call and Webcast Scheduled for Wednesday, May 9, 2018 at 8:00 a.m. ET MALVERN, Pa., May 02, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty...
-
MALVERN, Pa., April 30, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
-
MALVERN, Pa., April 16, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
-
MALVERN, Pa., March 29, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute...
-
MALVERN, Pa., March 27, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
-
MALVERN, Pa., March 21, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
-
MALVERN, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
-
MALVERN, Pa., March 05, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
-
MALVERN, Pa., March 02, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
-
IV Meloxicam NDA Submitted and PDUFA Action Date Set for May 26, 2018 Record CDMO Performance; 2017 Revenues of $71.8 Million MALVERN, Pa., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc....